Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06022224 · ClinicalTrials.gov registry record · Phase 2
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
A Phase 2 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT06022224 is a Phase 2 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 35 participants.
The verdict
NCT06022224, a Phase 2 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19. It is intended that a minimum of 25% of subjects will be in the \>55-year stratum. Safety, immunogenicity, and efficacy assessments will be conducted per the Schedule of Events (SoE) and subjects are expected to participate for up to a maximum of approximately 2 years.
Interventions
- BIOLOGICAL hAd5-S-Fusion+N-ETSD
- BIOLOGICAL Placebo (0.9% (w/v) saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06022224
The ClinicalTrials.gov registry entry for NCT06022224 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hAd5-S-Fusion+N-ETSD is the first listed.
NCT06022224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06022224 about?
NCT06022224 is a clinical study titled "A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL". This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19. It is intended that a minimum of 25% of subjects will be in the \>55-year stratum. Safety, im...
What is the current status of trial NCT06022224?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-12-09. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT06022224?
The interventions under investigation include: hAd5-S-Fusion+N-ETSD (BIOLOGICAL), Placebo (0.9% (w/v) saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06022224?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.